Wednesday, June 4, 2025
VISIT ROYALMOK
Agarwood Times
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
Agarwood Times
No Result
View All Result

Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots

February 11, 2025
in Health
Reading Time: 3 mins read
0 0
A A
0
Home Health
Share on FacebookShare on Twitter


Novartis is increasing its prospects in cardiometabolic illness by putting a deal to accumulate Anthos Therapeutics, an organization in pivotal testing with a blood clot-preventing drug that might provide benefits over anticoagulants at the moment offered by a few of its huge pharmaceutical friends.

In line with deal phrases introduced Tuesday, Novartis is paying $925 million up entrance for Anthos. Reaching milestones might convey the payout to as a lot as $3.1 billion. The deal, which nonetheless wants regulatory approvals, is anticipated to shut within the first half of this yr.

The acquisition represents a homecoming for Anthos’s fundamental asset, abelacimab, a drug that originated in Novartis’s labs. Anthos launched in 2019 with $250 million from Blackstone Life Sciences and a license for world rights to the Novartis drug, identified then as MAA868. On the time of the deal, this drug was in mid-stage scientific growth. Novartis retained a minority stake in Cambridge, Massachusetts-based Anthos.

Abelacimab is a monoclonal antibody designed to bind to a clotting protein referred to as Issue XI. Doing so is meant to dam activation of this protein that performs a key position in blood coagulation. Medication are already accessible to cut back the danger of stroke and blood clots. Xarelto, from Bayer and Johnson & Johnson, and Eliquis, marketed by Bristol Myers Squibb and Pfizer, are blockbuster sellers. However each blood-thinning medicines additionally include bleeding dangers.

Anthos already has scientific trial outcomes topping Xarelto. A Part 2 take a look at of abelacimab was stopped early in 2023 on account of “overwhelming discount in bleeding.” Detailed trial outcomes printed final month within the New England Journal of Medication present a 62% discount in main bleeding or clinically related non-major bleeding and a 67% discount in main bleeding in comparison with remedy with Xarelto. Anthos additionally reported its drug achieved an 89% discount in gastrointestinal bleeding.

Abelacimab, which is run intravenously at first after which by month-to-month subcutaneous injection thereafter, is at the moment in Part 3 testing in sufferers with atrial fibrillation who’ve a excessive threat for stroke or systemic embolism. Two further Part 3 research are underway testing the drug as a technique to stop the recurrence of blood clots in sufferers with most cancers. Anthos expects these research will put up knowledge within the second half of 2026.

“Abelacimab has the potential to be an vital remedy possibility for the thousands and thousands of sufferers globally with atrial fibrillation at excessive threat of stroke, and we couldn’t have extra conviction within the potential of this asset,” Anthos CEO Invoice Meury stated in a ready assertion. “With its deep roots within the cardiovascular area, Novartis is particularly properly positioned to advance abelacimab’s scientific growth and produce this revolutionary product to healthcare suppliers and sufferers.”

Cardiometabolic illness is one in every of 4 therapeutic areas that Novartis has recognized as core to its technique. The others are immunology, neuroscience, and oncology. The Anthos acquisition is well timed for Novartis. The Swiss pharma big’s cardiometabolic product lineup is at the moment anchored by Entresto, a coronary heart failure drug that accounted for $7.8 billion in worldwide gross sales in 2024, a 30% improve in comparison with the prior yr. However Entresto faces pricing challenges. Patents defending the product expire in 2025 and 2026. Entresto was additionally chosen as one of many first 10 medicine topic to cost negotiation by the Facilities for Medicare and Medicaid Providers. The negotiated value will take impact in 2026.

There have been different efforts to beat Xarelto and Eliquis. In 2023, Bayer stopped a Part 3 take a look at of asundexian in atrial fibrillation after the examine’s knowledge monitoring committee concluded the Issue XIa-blocking oral small molecule was unlikely to be more practical than Eliquis. In the meantime, Bristol Myers Squibb’s oral Issue XIa inhibitor milvexian is at the moment in Part 3 testing in acute coronary syndrome, atrial fibrillation, and secondary stroke prevention.

Picture: Magicmine, Getty Photos



Source link

Tags: 925MAcquisitionAnthosbloodBringsCardioClotsDrugNovartissStops
Previous Post

Pancreatic blood vessel cell map reveals potential diabetes treatment pathways

Next Post

What Is Lazy Keto and Should You Do It?

Related Posts

Household environments may affect the likelihood of children developing eczema
Health

Household environments may affect the likelihood of children developing eczema

June 4, 2025
Trump’s Cognitive ‘Decline’ Suggests He ‘Might Not Make It Through Four Years,’ Republican Strategist Says
Health

Trump’s Cognitive ‘Decline’ Suggests He ‘Might Not Make It Through Four Years,’ Republican Strategist Says

June 4, 2025
Monoclonal antibody halves hospitalizations of children younger than 6 months old
Health

Monoclonal antibody halves hospitalizations of children younger than 6 months old

June 3, 2025
Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia
Health

Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia

June 4, 2025
Guidance requiring hospitals to provide emergency abortions revoked
Health

Guidance requiring hospitals to provide emergency abortions revoked

June 4, 2025
Fine particulate matter exposure may alter pregnancy outcomes
Health

Fine particulate matter exposure may alter pregnancy outcomes

June 3, 2025
Next Post
What Is Lazy Keto and Should You Do It?

What Is Lazy Keto and Should You Do It?

2024 Fragrance Trends – WHAT’S NEXT for Fragrances?

2024 Fragrance Trends - WHAT'S NEXT for Fragrances?

Avian flu strikes more poultry flocks in 7 states and more cats

Avian flu strikes more poultry flocks in 7 states and more cats

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED

This Liver Disease Is Linked To Your Metabolism & How To Manage It
Diet & Fitness

This Liver Disease Is Linked To Your Metabolism & How To Manage It

by admin
May 31, 2025
0

At mindbodygreen, we do loads of reporting on all issues metabolic well being, from the risks of excessive blood sugar...

Woman dies from brain ameba after flushing nose with RV water

Woman dies from brain ameba after flushing nose with RV water

June 2, 2025
Majority of Americans do not recognize alcohol’s role in cancer risk

Majority of Americans do not recognize alcohol’s role in cancer risk

May 29, 2025
Fine particulate matter exposure may alter pregnancy outcomes

Fine particulate matter exposure may alter pregnancy outcomes

June 3, 2025
The Most Expensive Agar Tree |

The Most Expensive Agar Tree |

June 1, 2025
Eating healthier can protect aging brain

Eating healthier can protect aging brain

June 2, 2025
Facebook Twitter Instagram Youtube RSS
Agarwood Times

Stay informed with the latest news, articles, and insights on agarwood cultivation, history, sustainability, and more. Explore the timeless allure of agarwood and deepen your understanding of this extraordinary natural resource.

CATEGORIES

  • Agarwood
  • Diet & Fitness
  • Diseases
  • Health
  • Meditation
  • Nutrition
  • Sleep Info
  • Uncategorized
No Result
View All Result

SITEMAP

  • About us
  • Advertise With Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
VISIT ROYALMOK

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In